Autoimmune Uveitis - Epidemiology Forecast - 2036

Autoimmune Uveitis Insights and Trends

• According to DelveInsight's estimates, in 2025, there were nearly 670,000 diagnosed prevalent cases of autoimmune uveitis in the 7MM.
• Non-infectious uveitis affects approximately 121 per 100,000 people. It primarily affects people between the age of 20 and 60. Anterior uveitis is the most prevalent type accounting for 81% of uveitis patients, and about half of the cases are either recurring or chronic.
• Accurate identification of the underlying etiology is essential, particularly in severe, chronic, or non-anterior uveitis, as it guides management and prognosis. Patients with systemic involvement or a high risk of vision loss often require multidisciplinary care and specialist referral.
• According to secondary analysis, the pooled prevalence of non-infectious uveitis was estimated at 131.6 cases per 100,000 adults and 27.4 cases per 100,000 pediatric patients, while adult incidence reached 204.4 per 100,000 person-years, highlighting the increasing global burden of autoimmune uveitis.
• Autoimmune conditions such as ankylosing spondylitis, juvenile idiopathic arthritis, inflammatory bowel disease, sarcoidosis, and psoriatic arthritis continue to be major contributors to autoimmune uveitis prevalence.
• Despite its significant impact on vision, epidemiological and long-term outcome data for uveitis remain limited, largely relying on observational studies from specialized tertiary care centers.

DelveInsight's 'Autoimmune Uveitis - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the autoimmune uveitis, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Autoimmune Uveitis Understanding and Diagnosis Algorithm

Autoimmune Uveitis Overview

Autoimmune uveitis is an inflammatory process of uveal components due to an autoimmune reaction to self-antigens or is caused by an innate inflammatory reaction secondary to an external stimulus. It can present as an isolated entity or be associated with a systemic autoimmune or auto-inflammatory disease. In most cases, it affects the uvea but can also impact other parts of the eyes. It is categorized as infectious or noninfectious. Noninfectious Uveitis (NIU) can occur with systemic autoimmune disease and autoimmune diseases localized to the eye. Symptoms of NIU include ocular pain, photophobia, lacrimation, and redness. Common symptoms of uveitis are blurred vision, photophobia, eye pain, floaters (floating spots), headache, and injected conjunctiva; usually, children can be asymptomatic.

Autoimmune Uveitis Diagnosis

Autoimmune Uveitis Diagnosis begins with a comprehensive symptom review and a thorough exam of both the anterior and posterior segments. A systemic workup is initiated that includes laboratory testing for infectious and noninfectious etiologies, and a chest X-ray is also performed. Once this foundation has been laid, ancillary testing, including optical coherence tomography (OCT) and fluorescein angiography, can provide valuable insight. The patient journey begins when the patient gets affected by the risk factors such as, infection, surgery, genetic default, and others causing discomfort in the eye. The patient then goes to the general physician, who refer the patient to the ophthalmologist, who then ask the patient to go for diagnostic test such as, slit lamp examination, funduscopic exam, visual acuity test, and ocular pressure test to confirm the disease.

There is no universally accepted approach for the evaluation of uveitis. If the history, physical examination, and basic laboratory tests do not suggest a specific diagnosis, serologic studies for syphilis and chest radiography for sarcoidosis and tuberculosis are recommended.

Autoimmune Uveitis Epidemiology

Key Findings from Autoimmune Uveitis Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, in 2025, there were nearly 673, 000 diagnosed prevalent cases of autoimmune uveitis in the 7MM.
• In the 7MM, the US accounted for the highest number of diagnosed prevalent cases of uveitis, with nearly 377, 000 in 2025.
• In 2025, NIU accounted for the highest proportion of diagnosed prevalent cases of uveitis in the US, with approximately 90% of cases, while infectious uveitis accounted for the least, with around 10% of cases.
• Idiopathic uveitis represented the largest etiological segment in Japan in 2025, accounting for a substantially higher number of cases than other uveitis subtypes.
• Among EU4, Germany accounted for the largest number of diagnosed prevalent cases of uveitis followed by France, whereas Italy accounted for the lowest cases in 2025.
• NIU affects approximately 121 per 100,000 people. It primarily affects people between the age of 20 and 60. Anterior uveitis is the most prevalent type accounting for 81% of uveitis patients, and about half of the cases are either recurring or chronic.

Scope of the Report:

• The report covers a segment of an executive summary, a descriptive overview of autoimmune uveitis, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Autoimmune Uveitis Patient Population Forecast

Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of autoimmune uveitis ? What will be the growth opportunities across the 7MM concerning the patient population with autoimmune uveitis ?
• What is the historical and forecasted autoimmune uveitis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.